Reported Sunday, Ascentage Pharma Reports Lisaftoclax Plus AZA Shows 31.8% ORR In Venetoclax–Exposed Myeloid Malignancies

Benzinga · 2d ago
  • Preliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall response rate(ORR) in this subgroup of patients
  • 80% ORR achieved in newly diagnosed high-risk MDS/CMML
  • Strong safety profile with no dose-limiting toxicities across all patient cohorts in 103-patient study